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Abstract
We have found that a novel autoantibody against β2-glycoprotein I  
(β2GPI)/human leukocyte antigen (HLA) class II complexes (anti-β2GPI/HLA-DR) 
is involved in the pathogenesis of antiphospholipid syndrome (APS). It was also 
found that many APS patients who were negative for conventional antiphospholipid 
antibodies (aPLs) possessed anti-β2GPI/HLA-DR. These results suggested that 
anti-β2GPI/HLA-DR measurements may be more sensitive for diagnosing APS than 
conventional aPLs tests.  Recurrent pregnancy loss (RPL) is one of the clinical 
manifestations of APS. Therefore, a prospective, multicenter, cross-sectional study 
were conducted to assess whether anti-β2GPI/HLA-DR is also associated with RPL. 
This study of 227 couples with RPL revealed that 22.9% (52/227) of RPL women 
tested positive for anti-β2GPI/HLA-DR, and 24 (19.8%) of the 121 couples with 
unexplained RPL tested positive for anti-β2GPI/HLA-DR. Interestingly, thirty-five 
of the 52 (67.3%) RPL patients who were positive for anti-β2GPI/HLA-DR possessed 
no conventional aPLs of criteria. This novel autoantibody against β2GPI/HLA class 
II complexes may be a major risk factor for RPL, and it may be a promising bio-
marker for diagnosing APS.
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1. Introduction
It is well known that specific human leukocyte antigen (HLA) class II alleles 
are associated with susceptibility to many autoimmune diseases [1]. However, the 
mechanisms by which specific HLA class II molecules control the immune response 
in autoimmune diseases have been unclear. On the other hand, autoantibodies are 
produced in most autoimmune diseases and cause clinical manifestations of the 
diseases. It has also been an enigma how autoantibodies targeting self-antigens 
cause the autoimmune diseases. Arase et al. discovered a novel function of HLA 
class II molecules which are involved in the pathogenesis of certain autoimmune 
diseases [2–5].
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This review will focus on the autoantibodies associating with the novel func-
tion of HLA class II molecules and the pathogenesis of antiphospholipid  
syndrome (APS).
2.  The novel function of HLA class II molecules and autoimmune 
diseases
The classical function of HLA class II molecules is to present antigen peptides, 
derived from exogeneous proteins digested in lysosomes, to helper T-cells and by 
that to activate them.
Endogenous proteins, on the other hand, are formed and folded in the endo-
plasmic reticulum (ER). Correctly folded proteins are essential for cell survival and 
function. Therefore, it is believed that misfolded proteins generated in the ER are 
never transported to the extracellular space, because such proteins are eliminated 
by ER-associated degradation (ERAD).
However, Arase et al. discovered that misfolded proteins can be rescued from 
ERAD and transported to the cell surface without being processed into peptides. 
This process occurs in the ER via an association between the misfolded proteins and 
the peptide-binding groove of HLA class II molecules [2].
In addition, misfolded proteins complexed with HLA class II molecules of 
disease-susceptible alleles have been found to serve as targets of autoantibodies in 
certain autoimmune diseases, and to be involved in the disease pathogenesis. For 
example, immunoglobulin (Ig) G heavy chain complexed with HLA-DR and myelo-
peroxidase complexed with HLA-DR are major targets for autoantibodies in patients 
with rheumatoid arthritis and microscopic polyangiitis, respectively [3, 5].
3. The conventional concepts of antiphospholipid antibodies in APS
APS is diagnosed both by the presence of clinical manifestations, including 
vascular thrombosis and pregnancy morbidity, and by the presence of antiphospho-
lipid antibodies (aPLs) which present a laboratory criteria for APS [6]. Laboratory 
criteria for APS include IgG and IgM anticardiolipin antibodies (aCLs), IgG and 
IgM anti-β2-glycoprotein I (aβ2GPI) antibodies, and lupus anticoagulant (LAC). 
aPLs are thought to recognize linear β2-glycoprotein I (β2GPI), which undergoes 
conformational changes from the circular form of β2GPI by binding to negatively 
charged phospholipids [7], and cause APS by interacting with vascular endothelial 
cells [8]. Therefore, β2GPI bound to negatively charged phospholipids or nega-
tively charged plates is used clinically to detect autoantibodies in APS patients [9]. 
However, because autoantibodies against the β2GPI complexed to negatively charged 
phospholipids or high binding plates are detected in less than half of patients with 
clinical manifestations of APS [10–12], these facts suggest that additional targets 
of autoantibodies may exist. Furthermore, because β2GPI is a secreted protein, it 
cannot be universally present on the cell surface. Therefore, there might be other 
specific molecules which present β2GPI on the surface of vascular endothelial cells.
4.  The discovery of a novel autoantibody against β2GPI/HLA-DR 
complex in APS
We found that 293 T cells co-transfected with β2GPI and HLA-DR expressed 
both β2GPI and HLA-DR on the cell surface by flow cytometry analysis  
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(Figure 1) [4]. Conversely, 293 T cells transfected with only β2GPI did not express 
β2GPI on the cell surface, because β2GPI is a secreted protein (Figure 1) [4]. 
Immunoprecipitation and immunoblotting experiments revealed that full-length 
β2GPI proteins, but not peptide fragments of β2GPI, formed a complex with 
HLA-DR, and that these full-length β2GPI/HLA-DR complexes were present on 
the cell surface [4].
Furthermore, flow cytometry analysis revealed that not only the monoclonal 
antiphospholipid antibody derived from an APS patient (EY2C9), but also antibod-
ies in the sera of APS patients can bind to the β2GPI/HLA-DR complexes, even in 
the absence of phospholipids [4].
5.  Autoantibodies targeting β2GPI/HLA-DR complex are involved in the 
pathogenesis of APS
Immunofluorescence staining and in situ proximity-ligation assay (PLA), which 
detect close proximity (less than 40 nm) between two molecules [13], showed that 
β2GPI and HLA-DR were co-localized in endothelial cells of the placental decidua 
vessels from APS patients with spontaneous abortion. In contrast, no co-localization 
of β2GPI and HLA-DR was observed in placental tissues obtained from patients 
without APS [4].
In addition, we found that monoclonal antibody EY2C9 exhibited complement-
mediated cytotoxicity against 293 T cells expressing β2GPI together with the APS 
susceptibility allele HLA-DR7, however the cytotoxicity was not detected against 
293 T cells expressing HLA-DR7 alone or against those transfected with β2GPI 
alone [4].
HLA class II expression on endothelial cells is known to be induced after 
 exposure to cytokines, such as IFN-γ and TNF-α [14]. Therefore, inflammatory 
stimuli can induce HLA class II expression on vascular endothelial cells, and HLA 
class II molecules transport structurally altered β2GPI, which has high affinity for 
the peptide-binding grooves of the alleles of HLA class II. Autoantibodies against 
β2GPI/HLA class II complexes may damage vascular endothelial cells expressing 
β2GPI/HLA class II complexes in a complement-dependent manner and cause 
clinical manifestations of APS, including vascular thrombosis and pregnancy 
Figure 1. 
Monoclonal anti-phospholipid antibody binds to β2GPI/HLA-DR complex on the cell surface. 293 T 
cells transfected with only β2GPI did not express β2GPI on the cell surface, and human monoclonal anti-
phospholipid antibody (EY2C9) did not bind to these cells (the upper 3 histograms and 1 scheme). When β2GPI 
was co-transfected with HLA-DR into 293 T cells, β2GPI was expressed on the cell surface and was recognized 
by EY2C9 monoclonal antibody (the lower 3 histograms and 1 scheme). Abbreviations: HLA, human leukocyte 
antigen; β2GPI, β2-glycoprotein I; aPL mAb, anti-phospholipid monoclonal antibody.
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complications. In this way, β2GPI/HLA class II complexes and autoantibodies 
against the complexes may be involved in the pathogenesis of APS.
6. Alleles of HLA-DR complexed with β2GPI affect susceptibility to APS
HLA-DR4, HLA-DR7, and HLA-DR13 have been reported as susceptibility 
alleles for APS [15–18]. However, the mechanism by which these HLA class II alleles 
increase susceptibility to APS has remained an enigma.
To address this issue, we analyzed the ability of different HLA-DR alleles to 
transport β2GPI to the cell surface and found that HLA-DR7 and HLA-DR4 could 
transport much higher levels of β2GPI than other HLA-DR alleles recognized by the 
EY2C9 monoclonal antibody [4]. These results indicated that a binding affinity of 
β2GPI to each HLA-DR allele is important for autoantibody recognition of β2GPI/
HLA-DR complexes and is associated with differences in susceptibility to APS 
between different HLA-DR alleles.
7.  A method for quantifying serum levels of autoantibodies against 
β2GPI/HLA-DR complexes
We developed and modified a method to measure serum levels of autoantibodies 
against β2GPI/HLA-DR complexes (anti-β2GPI/HLA-DR) [4, 19].
Green fluorescent protein (GFP)-labeled β2GPI/HLA-DR complex-expressing 
293 T cells and DsRed-labeled HLA-DR-expressing 293 T cells were generated by 
transient transfection [19]. A serum sample from a patient in whom anti-β2GPI/
HLA-DR were detectable after a 106-fold dilution was used as a standard serum. The 
anti-β2GPI/HLA-DR level of a standard serum was defined as 1,000 units. The mean 
fluorescence intensity (MFI) of IgG binding to transfected cells in the sample sera 
was analyzed by flow cytometry. Specific IgG binding to the β2GPI/HLA-DR complex 
was calculated by subtracting the MFI of IgG binding to HLA-DR-expressing cells 
from β2GPI/HLA-DR complex-expressing cells. Serum levels of anti-β2GPI/HLA-DR 
in each sample were calculated from the standard curve generated by measuring spe-
cific IgG binding to the β2GPI/HLA-DR complex in serially diluted standard serum.
8.  Autoantibody against β2GPI/HLA-DR complex is a promising novel 
biomarker for APS
In our previous study, we measured serum levels of anti-β2GPI/HLA-DR in 
stored sera from 120 patients with APS, most of whom had a history of vascular 
thrombosis, and found that 83% of the 120 patients had autoantibodies directed 
against β2GPI/HLA-DR complexes. Furthermore, about 50% of the APS patients 
who tested positive for anti-β2GPI/HLA-DR (< 99th percentile values measured 
in sera of 100 healthy subjects) were negative for both IgG aCLs and IgG aβ2GPI 
antibodies [4]. Another recent study also showed that 27% of 111 patients with 
idiopathic chronic limb ulcers who were negative for aPLs possessed anti-β2GPI/
HLA-DR [20]. These results suggest that anti-β2GPI/HLA-DR are associated with 
APS manifestations, even in patients who do not meet the diagnostic criteria for 
APS because they are negative for conventional aPLs.
The latest prospective, multicenter, cross-sectional study, of 227 couples with 
recurrent pregnancy loss (RPL), which is one of the clinical manifestations of APS, 
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revealed that 22.9% (52/227) of women with RPL tested positive for anti-β2GPI/
HLA-DR (< 99th percentile values measured in sera of 208 healthy, fertile control 
women) [19]. In this study, anti-β2GPI/HLA-DR were detected most frequently 
in women with RPL among other commonly recognized risk factors for RPL, i.e., 
uterine malformation, thyroid dysfunction, chromosomal abnormality, aPLs 
positive, low factor XII activity, low protein S activity, and low protein C activity 
(Figure 2). Importantly, 53.3% (121/227) of women with RPL had no commonly 
accepted risk factors for RPL, and 24 of these 121 (19.8%) women with unexplained 
RPL were positive for anti-β2GPI/HLA-DR (Figure 2). In addition, 45 of the 227 
women with RPL (19.8%) were positive for at least one of the 5 conventional aPLs 
meeting the diagnostic criteria for APS in this study, i.e., IgG aCL (8.8%), IgM 
aCL (6.2%), IgG aβ2GPI (3.1%), IgM aβ2GPI (1.3%), and LAC (2.6%). The rate of 
positivity for anti-β2GPI/HLA-DR was the highest (22.9%) of the 5 aPLs that met 
the diagnostic criteria for APS. Notably, 35 (67.3%) of the 52 women with RPL who 
were positive for anti-β2GPI/HLA-DR, were negative for APS laboratory criteria 
(Figure 3).
On the other hand, the presence of multiple aPLs and LAC positivity has been 
reported to be strongly associated with the severity of clinical manifestations 
of APS [21–26]. In our study, all 3 women with RPL who had double or triple 
aPLs positivity were also positive for anti-β2GPI/HLA-DR, and the 2 with triple 
positivity had very high anti-β2GPI/HLA-DR levels (927.5 units and 330.7 units). 
First of both women experienced early-onset HELLP syndrome (hemolysis, 
elevated liver enzymes, and low platelets) at 14 weeks of gestation, and the 
second experienced a thromboembolism with cerebral infarction [19]. Multiple 
positivity for aPLs may be associated with higher levels of anti-β2GPI/HLA-DR, 
and these conditions may be closely associated with the severity of the clinical 
manifestations of APS.
Figure 2. 
Risk factors for recurrent pregnancy loss (RPL) among 227 women with RPL. All women with RPL enrolled 
in this study attended evaluations to identify commonly accepted risk factors for RPL. Black pie slices indicate 
the frequencies of women with RPL who were also positive for anti-β2GPI/HLA-DR (n = 52). Abbreviations: 
aPLs, antiphospholipid antibodies.
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9.  The future perspectives of the clinical use of autoantibodies targeting 
β2GPI/HLA-DR complexes
The standard treatment for pregnant women with APS is combination therapy 
with heparin and low-dose aspirin (LDA) [27], and the same therapy could also be 
effective in the treatment of women with RPL and anti-β2GPI/HLA-DR positivity. 
A cohort study is already underway to assess the efficacy of LDA and/or heparin 
therapy in such women. The history of vascular thrombosis and obstetric complica-
tions, including hypertensive disorders of pregnancy and fetal growth restriction, 
has not been investigated in prospective studies. Future studies assessing whether 
anti-β2GPI/HLA-DR are associated with thrombosis, hypertensive disorders of 
pregnancy, and fetal growth restriction are needed.
Further understanding of these novel autoantibodies associated with novel 
function of HLA class II molecules will provide new insights into the etiology of 
not only APS but also other autoimmune diseases and might lead to development of 
new treatment strategies for these diseases.
Figure 3. 
Positivity for anti-β2-glycoprotein I /HLA-DR antibodies (anti-β2GPI/HLA-DR) and antiphospholipid 
antibodies (aPLs) in 227 women with recurrent pregnancy loss (RPL). Numbers in the Venn diagram represent 
the number of women who had unique or nonunique results in tests for aPLs and anti-β2GPI/HLA-DR. 
abbreviations: Ig, immunoglobulin; HLA, human leukocyte antigen; β2GPI, β2-glycoprotein I; aβ2GPI, anti-
β2-glycoprotein I antibody; aCL, anti-cardiolipin antibody; LAC, lupus anticoagulant.
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